Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

62.40
+1.552.55%
Post-market: 62.35-0.0500-0.08%17:49 EDT
Volume:1.58M
Turnover:97.39M
Market Cap:6.05B
PE:26.69
High:62.51
Open:59.98
Low:59.62
Close:60.85
Loading ...

Sarepta Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
11 Apr

BUZZ-Sarepta rises after Wells Fargo starts coverage with 'overweight' rating

Reuters
·
11 Apr

Sarepta Therapeutics (SRPT) Receives a Buy from Morgan Stanley

TIPRANKS
·
11 Apr

Sarepta price target lowered to $112 from $150 at Guggenheim

TIPRANKS
·
10 Apr

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks
·
10 Apr

Top Stock Reports for Walmart, Coca-Cola & HSBC

Zacks
·
09 Apr

Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating

MT Newswires Live
·
07 Apr

Sarepta Therapeutics (SRPT) Receives a Hold from Scotiabank

TIPRANKS
·
07 Apr

Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital

TIPRANKS
·
05 Apr

Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials

MT Newswires Live
·
04 Apr

Sarepta price target lowered to $183 from $202 at Needham

TipRanks
·
04 Apr

Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS

TIPRANKS
·
04 Apr

Sarepta halts three studies testing gene therapy for muscle disorder

Reuters
·
04 Apr

Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

BRIEF-Sarepta Therapeutics Provides Update On Elevidys

Reuters
·
04 Apr

Sarepta Therapeutics: Studies Affected by Temporary Halt Are Study Srp-9001-302 (Envol), Study Srp-9001-303 (Envision), Study Srp-9001-104

THOMSON REUTERS
·
04 Apr

Sarepta Therapeutics Provides Update on Elevidys

THOMSON REUTERS
·
04 Apr

Sarepta Therapeutics: Co, Roche Will Submit Information in Response to Temporary Halt Within Week

THOMSON REUTERS
·
04 Apr

Sarepta Therapeutics Provides Update on ELEVIDYS

Business Wire
·
04 Apr

H.C. Wainwright sees increased uncertainty for Sarepta franchise

TIPRANKS
·
04 Apr